Spelling suggestions: "subject:"amedical care, most of--China--Hong long"" "subject:"amedical care, most of--China--Hong hong""
1 |
Health care financing options for Hong Kong何知行, Ho, Chi-hang, Bruce. January 2002 (has links)
published_or_final_version / Public Administration / Master / Master of Public Administration
|
2 |
An analysis of policy options to tackle the problem of expanding expenditure in public healthcare in Hong KongHon, Wai-ping, Tiki., 韓慧萍. January 1999 (has links)
published_or_final_version / Public Administration / Master / Master of Public Administration
|
3 |
Medical insurance: the solution to health care financing in Hong Kong?Fan, Yun-sun, Susan., 范瑩孫. January 1992 (has links)
published_or_final_version / Public Administration / Master / Master of Public Administration
|
4 |
Cost of coronary artery disease management in the public hospital setting in Hong Kong.January 2006 (has links)
Lam Lop Chi. / Thesis submitted in: August 2005. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2006. / Includes bibliographical references (leaves 114-126). / Abstracts in English and Chinese. / Acknowledgements --- p.I / Abstract in English --- p.II-IV / Abstract in Chinese --- p.V-VI / List of Abbreviations --- p.VII-IX / List of Figures --- p.X / List of Tables --- p.XI-XII / Table of Contents --- p.XIII-XV / Chapter Chapter 1 --- Introduction / Chapter 1.1 --- Background --- p.1 / Chapter 1.2 --- Risk factors --- p.6 / Chapter 1.3 --- Overseas guidelines in CAD management --- p.11 / Chapter 1.4 --- Angioplasty in CAD intervention --- p.15 / Chapter 1.5 --- Prevention or Intervention? --- p.21 / Chapter 1.6 --- Economic impact on PCI --- p.24 / Chapter 1.7 --- Cost of illness --- p.28 / Chapter 1.8 --- Hypothesis --- p.30 / Chapter 1.9 --- Objectives --- p.30 / Chapter Chapter 2 --- Cost of AMI Study / Chapter 2.1 --- Background --- p.31 / Chapter 2.2 --- Objective --- p.32 / Chapter 2.3 --- Method --- p.32 / Chapter 2.4 --- Results --- p.35 / Chapter 2.5 --- Discussion --- p.49 / Chapter 2.6 --- Study limitations --- p.58 / Chapter 2.7 --- Conclusions --- p.58 / Chapter Chapter 3 --- Angina study / Chapter 3.1 --- Background --- p.60 / Chapter 3.2 --- Objective --- p.76 / Chapter 3.3 --- Hypothesis --- p.76 / Chapter 3.4 --- Method --- p.76 / Chapter 3.5 --- Results --- p.79 / Chapter 3.6 --- Discussion --- p.93 / Chapter 3.7 --- Study limitations --- p.101 / Chapter 3.8 --- Conclusions --- p.101 / Chapter Chapter 4 --- Overall Discussion --- p.103 / Chapter Chapter 5 --- Conclusions --- p.112 / References --- p.114 / Appendix --- p.127
|
5 |
Cost of type 2 diabetes mellitus in Hong Kong Chinese and economic analysis of a new antidiabetic agent.January 2006 (has links)
Chan Siu-Wah. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2006. / Includes bibliographical references (leaves 173-200). / Abstracts in English and Chinese; appendix in Chinese. / Table of Contents --- p.i / Abstract --- p.v / 論文摘要 --- p.ix / Acknowledgments --- p.xii / Table of Figures --- p.xiii / Table of Tables --- p.xvii / Chapter Chapter 1. --- Introduction --- p.1 / Chapter Chapter 2. --- Literature Review --- p.3 / Chapter 2.1 --- Diabetes Mellitus (DM): Overview --- p.3 / Chapter 2.1.1 --- Diagnosis and Diagnostic Criteria --- p.4 / Chapter 2.1.2 --- Classifications of Diabetes Mellitus --- p.8 / Chapter 2.1.3 --- Management of Type 2 Diabetes Mellitus --- p.15 / Chapter 2.2 --- Diabetes Mellitus Complications: Overview --- p.25 / Chapter 2.2.1 --- Microvascular Complications --- p.26 / Chapter 2.2.2 --- Macrovascular Complications --- p.31 / Chapter 2.3 --- Type 2 Diabetes Mellitus - A Rising Global Burden --- p.32 / Chapter 2.3.1 --- Prevalence of Type 2 Diabetes Mellitus --- p.32 / Chapter 2.3.2 --- Prevalence of Type 2 Diabetes Mellitus in Hong Kong --- p.36 / Chapter 2.3.3 --- Mortality and Morbidity of Type 2 Diabetes Mellitus in Hong Kong --- p.40 / Chapter 2.4 --- cost of Type 2 Diabetes Mellitus - Under-explored Area in Hong Kong and Asia --- p.46 / Chapter 2.4.1 --- Cost of Type 2 Diabetes Mellitus in the USA --- p.48 / Chapter 2.4.2 --- Cost of Type 2 Diabetes Mellitus in Europe --- p.57 / Chapter 2.4.3 --- Cost of Type 2 Diabetes Mellitus in Asia-Pacific --- p.61 / Chapter 2.5 --- Hong Kong Healthcare System --- p.65 / Chapter 2.5.1 --- Hospital Authority in Hong Kong (Public Healthcare Sector) --- p.67 / Chapter 2.5.2 --- Hong Kong Healthcare Financing System --- p.73 / Chapter 2.6 --- New Emerging Drug Treatment for Type 2 DM in Hong Kong Chinese - Rosiglitazone --- p.77 / Chapter 2.6.1 --- Clinical Efficacy and Tolerability of Rosiglitazone --- p.77 / Chapter 2.6.2 --- Cost-effectiveness of Rosiglitazone --- p.78 / Chapter Chapter 3. --- Hypothesis and Objectives --- p.81 / Chapter 3.1 --- Cost of Type 2 Diabetes Mellitus in Hong Kong Chinese --- p.81 / Chapter 3.1.1 --- Hypothesis --- p.81 / Chapter 3.1.2 --- Objectives --- p.81 / Chapter 3.2 --- Cost-effectiveness Analysis of Metformin + Rosiglitazone vs. Metformin + Glibenclamide for Type 2 DM Patient Whose Diabetes is not Adequately Controlled by Metformin Alone from a Payer's Perspective --- p.82 / Chapter 3.2.1 --- Hypothesis --- p.82 / Chapter 3.2.2 --- Objectives --- p.83 / Chapter Chapter 4. --- Cost of Type 2 Diabetes Mellitus in Hong Kong Chinese --- p.84 / Chapter 4.1 --- Subjects and Methods --- p.84 / Chapter 4.1.1 --- Subjects --- p.84 / Chapter 4.1.2 --- Methods --- p.85 / Chapter 4.1.3 --- Validity and Reliability of the Chinese Questionnaire --- p.96 / Chapter 4.2 --- Results --- p.96 / Chapter 4.2.1 --- Subjects' Characteristics --- p.96 / Chapter 4.2.3 --- Comorbidity --- p.102 / Chapter 4.2.4 --- Complications --- p.102 / Chapter 4.2.5 --- Costs of Type 2 DM --- p.104 / Chapter 4.3 --- Discussions --- p.123 / Chapter Chapter 5 --- Cost-effectiveness Analysis of Metformin + Rosiglitazone vs. Metformin + Glibenclamide for Type 2 DM Patient Whose Diabetes is not Adequately Controlled by Metformin Alone from a Payer's Perspective --- p.134 / Chapter 5.1 --- Methods --- p.134 / Chapter 5.1.1 --- Model Overview --- p.134 / Chapter 5.1.2 --- "Success, Failure and Discontinuation Rates" --- p.138 / Chapter 5.1.3 --- Resources Use and Costs --- p.142 / Chapter 5.1.4 --- Health-Related Quality of Life (HRQOL) --- p.148 / Chapter 5.1.5 --- Base Case Analysis --- p.149 / Chapter 5.1.6 --- Sensitivity Analyses --- p.149 / Chapter 5.2 --- Results --- p.150 / Chapter 5.2.1 --- Base Case Model - CE Analysis: cost per controlled Type 2 DM patient --- p.150 / Chapter 5.2.2 --- Sensitivity Analysis- CE Analysis: cost per controlled Type 2 DM patient --- p.151 / Chapter 5.2.3 --- Base Case Model - CE Analysis: cost per EQ5D utility score --- p.154 / Chapter 5.2.4 --- Sensitivity Analysis- CE Analysis: cost per EQ5D utility score --- p.155 / Chapter 5.3 --- Discussions --- p.158 / Chapter Chapter 6. --- Conclusions --- p.163 / Appendix --- p.165 / References
|
Page generated in 4.5133 seconds